Immuno-Oncology 360° Community News’ Post

Despite the slower 1H of 2024, Q3 seems to be hotting up on the funding side. Reveal-Dx is the latest to announce a successful round, with $4.2m. This follows AIRS Medical, whom secured $20m in Series C funding, and Eden (a PACS vendor in Latin America) announced an additional $10m in funding. Although the market is unlikely to see the heights of previous years, vendors efforts in 1H 2024 are coming to fruition. By the end of the year, we will see those that have secured another year of operations, and those who may be at risk of exiting the market in 2025.... #funding #vcfunding #AI #PACS

Heading to #ASCO2024? Connect with our clinical leadership team at Booth #11118 for an exclusive demo! Velsera's CGW and clinical-grade Knowledgebase streamline patient treatment decisions by evaluating variant significance, supporting target identification, and generating reports with tailored therapeutic options, saving time and ensuring high-quality outcomes. But wait, there's a whole lot more! Velsera drives new drug discoveries supporting pre-clinical and clinical development, sparking exponential advances in human health. With cutting-edge AI-powered technology, we fuel innovation in healthcare and life sciences, reshaping the industry landscape from R&D to bedside analytics. Our Seven Bridges Platform expedites drug discovery, enhances quality, and reduces costs. Unlock the power of multi-omics data analysis, enhancing precision by more than 50%. From target identification to clinical trials, our solutions support every stage of drug discovery. Schedule a meeting to uncover how we can help you drive the future of precision medicine! https://lnkd.in/gQET4ERf #ASCO24 #Oncology #CancerResearch #EraofVelsera

Heading to #ASCO2024? Connect with our clinical leadership team at Booth #11118 for an exclusive demo! Velsera's CGW and clinical-grade Knowledgebase streamline patient treatment decisions by evaluating variant significance, supporting target identification, and generating reports with tailored therapeutic options, saving time and ensuring high-quality outcomes. But wait, there's a whole lot more! Velsera drives new drug discoveries supporting pre-clinical and clinical development, sparking exponential advances in human health. With cutting-edge AI-powered technology, we fuel innovation in healthcare and life sciences, reshaping the industry landscape from R&D to bedside analytics. Our Seven Bridges Platform expedites drug discovery, enhances quality, and reduces costs. Unlock the power of multi-omics data analysis, enhancing precision by more than 50%.  From target identification to clinical trials, our solutions support every stage of drug discovery. Schedule a meeting to uncover how we can help you drive the future of precision medicine! https://lnkd.in/gnjwqaTM #ASCO24 #Oncology #CancerResearch #EraofVelsera

Check out Illumina's video highlights from ESMO 2023 below!

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/dPyKdFxP #ChooseCalyx #MedicalImaging

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/eN4ifRVJ #ChooseCalyx #MedicalImaging

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/eEXcpyUS #ChooseCalyx #MedicalImaging

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/eseeTz9d #ChooseCalyx #MedicalImaging

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/evWheH44 #ChooseCalyx #MedicalImaging

Assessing #prostatecancer in #clinicaltrials is challenging ‒ from protocol design and image acquisition to the implementation of assessment criteria, lesion counting rules, and read models. Learn Calyx’s recommendations for successful imaging in #PCa clinical trials. https://lnkd.in/gPpagQgd #ChooseCalyx #MedicalImaging